Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Basile

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Postgraduate Medicine|December 14, 2011
2011 Recommendations for the diagnosis and management of gout and hyperuricemiaMax Hamburger, Herbert S B Baraf, Thomas C Adamson, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
JAMA|February 28, 2023
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical TrialMichel Azizi, Manish Saxena, Yale Wang, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Postgraduate Medicine|December 14, 2011
2011 Recommendations for the diagnosis and management of gout and hyperuricemiaMax Hamburger, Herbert S B Baraf, Thomas C Adamson, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
JAMA|February 28, 2023
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical TrialMichel Azizi, Manish Saxena, Yale Wang, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
Pageof 8